Does Methotrexate Increase Skin Cancer Risk? A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses. https://t.co/tNNpFC6LiN https://t.co/x8Fuus2r8O

Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE. https://t.co/0g2VM6TJt6 https://t.co/f6wylPc5ep

Recent Cochrane review of Vit D, Calcium and OP shows no evidence to support the isolated or combined use of calcium & vit D in premenopausal women to improve BMD (hip or spine) or results in the prevention of fractures (vertebral and non‐vertebral). https://t.co/ZbXuPAJcGv https://t.co/pai4gmMKoI

Retrospective cohort study of Taiwan Health Insurance Database looked at risk of #SLE in pts w/ Hashimoto’s thyroiditis (HT). Compared 15K HTvs 31K controls. SLE was incr in HT pts (IRR 3.58; p < 0.01). Several sensitivity analyses aHR 4.35 to 5.11 https://t.co/QaWEN4Chw9 https://t.co/bD8zrCJEXY

NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/VICAqKmK9r https://t.co/MxqcNzh6BQ

New 5 Peptide Autoantibody Panel Complements RA Diagnosis Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said. https://t.co/lOZvXBp7c1 https://t.co/6JVpeOyGYu

Systemic Sclerosis cohort study of 506 SSc pts with saw 5.3 with Degos-like lesions (89% in fingers). Degos lesions more assoc w/ diffuseSSc & acro-osteolysis, digital ulcers, and calcinosis (but not renal crisis, ILD, or pulmonary HTN https://t.co/eCumzZvEmO https://t.co/B41NLt4RYF

Multicenter study of 80 AOSD & 60 controls used to develop AOSD criteria: - 3 pts rash - 3pts fever ≥ 39C - 2 pts pharyngitis - 2 pts arthritis - 2 pts NLR ≥ 4 - 1 pt glycosyl ferritin ≤ 20% 7 pts = Dx (sens 92.5%) vs Yamaguchi(79%), Fautrel (76%) https://t.co/UvtSABRs8s https://t.co/LzqWdyaj8h

Full read, solid review of Diagnosis and management of autoimmune hepatitis from BMJ https://t.co/mc1ozL6CG8 https://t.co/xQkX7WpETv

Pregnancy & RA: metanalysis of 9 studies, 12K RA pts met vs 10 million controls. RA preg have more maternal complications (C sect OR 1.55; preeclampsia OR, 1.6; preterm OR, 1.8) & neonatal probs (low gestat wt, ICU OR 1.34, & stillbirths OR, 1.99). https://t.co/1hA0zGsDtk https://t.co/awaV07GbEv

Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! RheumNow Live is unlike any meeting you've ever attended. Here's why: -Inspired Education -The Audience Matters - A meeting designed to change your mind and practice. https://t.co/wWjsjWATdv https://t.co/Rd7O3Yhpw3

Early ph II Pilot trial of 30 Systemic Sclerosis Pts using a new antifibrotic FT011 400mg vs 200mg v PBO x 12 wks showed CRISS score improved by 60% (400mg; (p=0.02 ) or 20% (200mg) at 12wks. An OL extension is planned for 9 mos @400 mg/d. https://t.co/ZU5wGXMDMC https://t.co/9kp20kfuCn